Comparing Older and Newer Antipsychotic Treatment Strategies
About this title
Read the official source — NCT01164059This study evaluated the effectiveness of Olanzapine for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Olanzapine for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Aachen and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 149
- Sponsor
- University of Bremen
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Germany
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01164059
- Official title
Show the full official title
Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Aachen · Angermünde · Bad Zwischenahn
14 more locations
- Berlin
- Bochum
- Bremen
- Düsseldorf
- Eisenhüttenstadt
- Göttingen
- Hamburg
- Hanover
- Liebenburg
- Neubrandenburg
- Neuruppin
- Potsdam
- Rüdersdorf
- Taufkirchen
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Olanzapine for people with schizophrenia.
Who is behind this study?
The study sponsor is University of Bremen, a university.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine, Flupentixol, Quetiapine, Aripiprazole and Haloperidol.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
